These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38582179)

  • 1. Can (Natural) deep eutectic systems increase the efficacy of ocular therapeutics?
    Sarmento C; Duarte ARC; Rita Jesus A
    Eur J Pharm Biopharm; 2024 May; 198():114276. PubMed ID: 38582179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Nanotherapies for the Posterior Segment of the Eye: An Integrative Review on Recent Advancements and Challenges.
    Gogoi NR; Marbaniang D; Pal P; Ray S; Mazumder B
    Pharm Nanotechnol; 2022 Nov; 10(4):268-278. PubMed ID: 35946098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern drug delivery systems for targeting the posterior segment of the eye.
    Peptu CA; Popa M; Savin C; Popa RF; Ochiuz L
    Curr Pharm Des; 2015; 21(42):6055-69. PubMed ID: 26503152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New techniques for drug delivery to the posterior eye segment.
    Eljarrat-Binstock E; Pe'er J; Domb AJ
    Pharm Res; 2010 Apr; 27(4):530-43. PubMed ID: 20155388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.
    Mandal A; Bisht R; Rupenthal ID; Mitra AK
    J Control Release; 2017 Feb; 248():96-116. PubMed ID: 28087407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.
    Shatz W; Aaronson J; Yohe S; Kelley RF; Kalia YN
    Expert Opin Drug Deliv; 2019 Jan; 16(1):43-57. PubMed ID: 30488721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation therapeutics for retinal neurodegenerative diseases.
    Appell MB; Pejavar J; Pasupathy A; Rompicharla SVK; Abbasi S; Malmberg K; Kolodziejski P; Ensign LM
    J Control Release; 2024 Mar; 367():708-736. PubMed ID: 38295996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell penetrating peptides in ocular drug delivery: State of the art.
    Pescina S; Ostacolo C; Gomez-Monterrey IM; Sala M; Bertamino A; Sonvico F; Padula C; Santi P; Bianchera A; Nicoli S
    J Control Release; 2018 Aug; 284():84-102. PubMed ID: 29913221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Natural Deep Eutectic Systems as Alternative Media for Ocular Applications.
    Sarmento C; Monteiro H; Paiva A; Duarte ARC; Jesus AR
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan.
    Burhan AM; Klahan B; Cummins W; Andrés-Guerrero V; Byrne ME; O'Reilly NJ; Chauhan A; Fitzhenry L; Hughes H
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.
    Hartnett TE; O'Connor AJ; Ladewig K
    Expert Opin Drug Deliv; 2015; 12(9):1513-26. PubMed ID: 25745885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical devices for the treatment of eye diseases.
    Yasukawa T; Ogura Y
    Handb Exp Pharmacol; 2010; (197):469-89. PubMed ID: 20217540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.